#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Cancer has been a major threat to human health in recent years .
2-1	16-22	Cancer	abstract	new	coref	2-4[3_0]
2-2	23-26	has	_	_	_	_
2-3	27-31	been	_	_	_	_
2-4	32-33	a	abstract[3]	giv[3]	coref	4-13[0_3]
2-5	34-39	major	abstract[3]	giv[3]	_	_
2-6	40-46	threat	abstract[3]	giv[3]	_	_
2-7	47-49	to	abstract[3]	giv[3]	_	_
2-8	50-55	human	abstract[3]|abstract[4]	giv[3]|new[4]	_	_
2-9	56-62	health	abstract[3]|abstract[4]	giv[3]|new[4]	_	_
2-10	63-65	in	abstract[3]	giv[3]	_	_
2-11	66-72	recent	abstract[3]|time[5]	giv[3]|new[5]	coref	3-2[6_5]
2-12	73-78	years	abstract[3]|time[5]	giv[3]|new[5]	_	_
2-13	79-80	.	_	_	_	_

#Text=In the past forty years , even though great efforts have been made , there is still much to be done before a safe therapy is achieved .
3-1	81-83	In	_	_	_	_
3-2	84-87	the	time[6]	giv[6]	_	_
3-3	88-92	past	time[6]	giv[6]	_	_
3-4	93-98	forty	time[6]	giv[6]	_	_
3-5	99-104	years	time[6]	giv[6]	_	_
3-6	105-106	,	_	_	_	_
3-7	107-111	even	_	_	_	_
3-8	112-118	though	_	_	_	_
3-9	119-124	great	event[7]	new[7]	_	_
3-10	125-132	efforts	event[7]	new[7]	_	_
3-11	133-137	have	_	_	_	_
3-12	138-142	been	_	_	_	_
3-13	143-147	made	_	_	_	_
3-14	148-149	,	_	_	_	_
3-15	150-155	there	_	_	_	_
3-16	156-158	is	_	_	_	_
3-17	159-164	still	_	_	_	_
3-18	165-169	much	_	_	_	_
3-19	170-172	to	_	_	_	_
3-20	173-175	be	_	_	_	_
3-21	176-180	done	_	_	_	_
3-22	181-187	before	_	_	_	_
3-23	188-189	a	event[8]	new[8]	coref	7-7[28_8]
3-24	190-194	safe	event[8]	new[8]	_	_
3-25	195-202	therapy	event[8]	new[8]	_	_
3-26	203-205	is	_	_	_	_
3-27	206-214	achieved	_	_	_	_
3-28	215-216	.	_	_	_	_

#Text=Currently , chemotherapy and radiotherapy are still the main therapeutic methods for cancer .
4-1	217-226	Currently	_	_	_	_
4-2	227-228	,	_	_	_	_
4-3	229-241	chemotherapy	abstract	new	_	_
4-4	242-245	and	_	_	_	_
4-5	246-258	radiotherapy	abstract	new	coref	4-7[11_0]
4-6	259-262	are	_	_	_	_
4-7	263-268	still	abstract[11]	giv[11]	_	_
4-8	269-272	the	abstract[11]	giv[11]	_	_
4-9	273-277	main	abstract[11]	giv[11]	_	_
4-10	278-289	therapeutic	abstract[11]	giv[11]	_	_
4-11	290-297	methods	abstract[11]	giv[11]	_	_
4-12	298-301	for	abstract[11]	giv[11]	_	_
4-13	302-308	cancer	abstract[11]|abstract	giv[11]|giv	ana	6-3
4-14	309-310	.	_	_	_	_

#Text=However , most of the anticancer drugs have toxic side effects .
5-1	311-318	However	_	_	_	_
5-2	319-320	,	_	_	_	_
5-3	321-325	most	substance[14]	new[14]	coref	6-8[18_14]
5-4	326-328	of	substance[14]	new[14]	_	_
5-5	329-332	the	substance[14]	new[14]	_	_
5-6	333-343	anticancer	abstract|substance[14]	new|new[14]	coref	6-9
5-7	344-349	drugs	substance[14]	new[14]	_	_
5-8	350-354	have	_	_	_	_
5-9	355-360	toxic	abstract[15]	new[15]	coref	6-13[20_15]
5-10	361-365	side	abstract[15]	new[15]	_	_
5-11	366-373	effects	abstract[15]	new[15]	_	_
5-12	374-375	.	_	_	_	_

#Text=Therefore , it is critical to develop novel anticancer drugs that have no toxic side effects on other tissues or organs in vivo , and only target the lesion area .
6-1	376-385	Therefore	_	_	_	_
6-2	386-387	,	_	_	_	_
6-3	388-390	it	abstract	giv	coref	7-17
6-4	391-393	is	_	_	_	_
6-5	394-402	critical	_	_	_	_
6-6	403-405	to	_	_	_	_
6-7	406-413	develop	event	new	coref|none	17-10[121_0]|6-7[0_205]
6-8	414-419	novel	substance[18]	giv[18]	coref	7-3[26_18]
6-9	420-430	anticancer	abstract|substance[18]	giv|giv[18]	coref	15-15
6-10	431-436	drugs	substance[18]	giv[18]	_	_
6-11	437-441	that	substance[18]	giv[18]	_	_
6-12	442-446	have	substance[18]	giv[18]	_	_
6-13	447-449	no	substance[18]|abstract[20]	giv[18]|giv[20]	_	_
6-14	450-455	toxic	substance[18]|abstract[20]	giv[18]|giv[20]	_	_
6-15	456-460	side	substance[18]|abstract|abstract[20]	giv[18]|new|giv[20]	_	_
6-16	461-468	effects	substance[18]|abstract[20]	giv[18]|giv[20]	_	_
6-17	469-471	on	substance[18]|abstract[20]	giv[18]|giv[20]	_	_
6-18	472-477	other	substance[18]|abstract[20]|object[21]	giv[18]|giv[20]|new[21]	_	_
6-19	478-485	tissues	substance[18]|abstract[20]|object[21]	giv[18]|giv[20]|new[21]	_	_
6-20	486-488	or	substance[18]|abstract[20]	giv[18]|giv[20]	_	_
6-21	489-495	organs	substance[18]|abstract[20]|object[22]	giv[18]|giv[20]|new[22]	_	_
6-22	496-498	in	substance[18]|abstract[20]|object[22]	giv[18]|giv[20]|new[22]	_	_
6-23	499-503	vivo	substance[18]|abstract[20]|object[22]|abstract	giv[18]|giv[20]|new[22]|new	_	_
6-24	504-505	,	substance[18]	giv[18]	_	_
6-25	506-509	and	substance[18]	giv[18]	_	_
6-26	510-514	only	substance[18]	giv[18]	_	_
6-27	515-521	target	substance[18]	giv[18]	_	_
6-28	522-525	the	substance[18]|place[25]	giv[18]|new[25]	coref	20-12[144_25]
6-29	526-532	lesion	substance[18]|abstract|place[25]	giv[18]|new|new[25]	_	_
6-30	533-537	area	substance[18]|place[25]	giv[18]|new[25]	_	_
6-31	538-539	.	_	_	_	_

#Text=Compared with traditional chemotherapeutic drugs , the nano-anticancer drug therapy has potential application prospects in curing cancer diseases .
7-1	540-548	Compared	_	_	_	_
7-2	549-553	with	_	_	_	_
7-3	554-565	traditional	substance[26]	giv[26]	coref	8-7[36_26]
7-4	566-582	chemotherapeutic	substance[26]	giv[26]	_	_
7-5	583-588	drugs	substance[26]	giv[26]	_	_
7-6	589-590	,	_	_	_	_
7-7	591-594	the	event[28]	giv[28]	_	_
7-8	595-610	nano-anticancer	event[28]	giv[28]	_	_
7-9	611-615	drug	substance|event[28]	new|giv[28]	_	_
7-10	616-623	therapy	event[28]	giv[28]	_	_
7-11	624-627	has	_	_	_	_
7-12	628-637	potential	abstract[30]	new[30]	_	_
7-13	638-649	application	abstract|abstract[30]	new|new[30]	_	_
7-14	650-659	prospects	abstract[30]	new[30]	_	_
7-15	660-662	in	_	_	_	_
7-16	663-669	curing	_	_	_	_
7-17	670-676	cancer	abstract|abstract[32]	giv|new[32]	coref	23-10
7-18	677-685	diseases	abstract[32]	new[32]	_	_
7-19	686-687	.	_	_	_	_

#Text=One of the major concerns about the nano-anticancer drugs is the drug-delivery vector .
8-1	688-691	One	abstract[33]	new[33]	coref	8-11[37_33]
8-2	692-694	of	abstract[33]	new[33]	_	_
8-3	695-698	the	abstract[33]|abstract[34]	new[33]|new[34]	_	_
8-4	699-704	major	abstract[33]|abstract[34]	new[33]|new[34]	_	_
8-5	705-713	concerns	abstract[33]|abstract[34]	new[33]|new[34]	_	_
8-6	714-719	about	abstract[33]|abstract[34]	new[33]|new[34]	_	_
8-7	720-723	the	abstract[33]|abstract[34]|substance[36]	new[33]|new[34]|giv[36]	coref	13-39[0_36]
8-8	724-739	nano-anticancer	abstract[33]|abstract[34]|abstract|substance[36]	new[33]|new[34]|new|giv[36]	_	_
8-9	740-745	drugs	abstract[33]|abstract[34]|substance[36]	new[33]|new[34]|giv[36]	_	_
8-10	746-748	is	_	_	_	_
8-11	749-752	the	abstract[37]	giv[37]	coref	9-1[39_37]
8-12	753-766	drug-delivery	abstract[37]	giv[37]	_	_
8-13	767-773	vector	abstract[37]	giv[37]	_	_
8-14	774-775	.	_	_	_	_

#Text=The ideal delivery vector should possess such characteristics as a high drug-loading capacity , low immunogenicity , low toxicity , better shelf-life , and water solubility , and it should have the potential to be further modified .
9-1	776-779	The	abstract[39]	giv[39]	coref	29-35[219_39]
9-2	780-785	ideal	abstract[39]	giv[39]	_	_
9-3	786-794	delivery	abstract|abstract[39]	new|giv[39]	coref	11-12
9-4	795-801	vector	abstract[39]	giv[39]	_	_
9-5	802-808	should	_	_	_	_
9-6	809-816	possess	_	_	_	_
9-7	817-821	such	abstract[40]	new[40]	_	_
9-8	822-837	characteristics	abstract[40]	new[40]	_	_
9-9	838-840	as	abstract[40]	new[40]	_	_
9-10	841-842	a	abstract[40]|abstract[42]	new[40]|new[42]	_	_
9-11	843-847	high	abstract[40]|abstract[42]	new[40]|new[42]	_	_
9-12	848-860	drug-loading	abstract[40]|substance|abstract[42]	new[40]|new|new[42]	_	_
9-13	861-869	capacity	abstract[40]|abstract[42]	new[40]|new[42]	_	_
9-14	870-871	,	abstract[40]	new[40]	_	_
9-15	872-875	low	abstract[40]|abstract[43]	new[40]|new[43]	_	_
9-16	876-890	immunogenicity	abstract[40]|abstract[43]	new[40]|new[43]	_	_
9-17	891-892	,	abstract[40]	new[40]	_	_
9-18	893-896	low	abstract[40]|abstract[44]	new[40]|new[44]	coref	23-38[172_44]
9-19	897-905	toxicity	abstract[40]|abstract[44]	new[40]|new[44]	_	_
9-20	906-907	,	abstract[40]	new[40]	_	_
9-21	908-914	better	abstract[40]|abstract[45]	new[40]|new[45]	_	_
9-22	915-925	shelf-life	abstract[40]|abstract[45]	new[40]|new[45]	_	_
9-23	926-927	,	abstract[40]	new[40]	_	_
9-24	928-931	and	abstract[40]	new[40]	_	_
9-25	932-937	water	abstract[40]|substance|substance[47]	new[40]|new|new[47]	ana	9-29[0_47]
9-26	938-948	solubility	abstract[40]|substance[47]	new[40]|new[47]	_	_
9-27	949-950	,	_	_	_	_
9-28	951-954	and	_	_	_	_
9-29	955-957	it	substance	giv	_	_
9-30	958-964	should	_	_	_	_
9-31	965-969	have	_	_	_	_
9-32	970-973	the	abstract[49]	new[49]	_	_
9-33	974-983	potential	abstract[49]	new[49]	_	_
9-34	984-986	to	abstract[49]	new[49]	_	_
9-35	987-989	be	abstract[49]	new[49]	_	_
9-36	990-997	further	abstract[49]	new[49]	_	_
9-37	998-1006	modified	abstract[49]	new[49]	_	_
9-38	1007-1008	.	_	_	_	_

#Text=Synthetic polymers , such as , chitosan , polyetherimide ( PEI ) , poly(lactic-co-glycolic acid ) ( PLGA ) , polyamidoamine ( PAMAM ) , and poly-l-lactic acid ( PLA ) have been widely used in gene- and drug-delivery systems .
10-1	1009-1018	Synthetic	substance[50]	new[50]	_	_
10-2	1019-1027	polymers	substance[50]	new[50]	_	_
10-3	1028-1029	,	substance[50]	new[50]	_	_
10-4	1030-1034	such	substance[50]	new[50]	_	_
10-5	1035-1037	as	substance[50]	new[50]	_	_
10-6	1038-1039	,	substance[50]	new[50]	_	_
10-7	1040-1048	chitosan	substance[50]|plant	new[50]|new	_	_
10-8	1049-1050	,	substance[50]	new[50]	_	_
10-9	1051-1065	polyetherimide	substance[50]|abstract	new[50]|new	_	_
10-10	1066-1067	(	substance[50]	new[50]	_	_
10-11	1068-1071	PEI	substance[50]|person	new[50]|new	_	_
10-12	1072-1073	)	substance[50]	new[50]	_	_
10-13	1074-1075	,	substance[50]	new[50]	_	_
10-14	1076-1099	poly(lactic-co-glycolic	substance[50]|abstract|substance[55]	new[50]|new|new[55]	_	_
10-15	1100-1104	acid	substance[50]|substance[55]	new[50]|new[55]	_	_
10-16	1105-1106	)	substance[50]	new[50]	_	_
10-17	1107-1108	(	substance[50]	new[50]	_	_
10-18	1109-1113	PLGA	substance[50]	new[50]	_	_
10-19	1114-1115	)	substance[50]	new[50]	_	_
10-20	1116-1117	,	substance[50]	new[50]	_	_
10-21	1118-1132	polyamidoamine	substance[50]|substance	new[50]|new	_	_
10-22	1133-1134	(	substance[50]	new[50]	_	_
10-23	1135-1140	PAMAM	substance[50]|abstract	new[50]|new	_	_
10-24	1141-1142	)	substance[50]	new[50]	_	_
10-25	1143-1144	,	substance[50]	new[50]	_	_
10-26	1145-1148	and	substance[50]	new[50]	_	_
10-27	1149-1162	poly-l-lactic	substance[50]|abstract|substance[59]	new[50]|new|new[59]	_	_
10-28	1163-1167	acid	substance[50]|substance[59]	new[50]|new[59]	_	_
10-29	1168-1169	(	_	_	_	_
10-30	1170-1173	PLA	abstract	new	_	_
10-31	1174-1175	)	_	_	_	_
10-32	1176-1180	have	_	_	_	_
10-33	1181-1185	been	_	_	_	_
10-34	1186-1192	widely	_	_	_	_
10-35	1193-1197	used	_	_	_	_
10-36	1198-1200	in	_	_	_	_
10-37	1201-1206	gene-	abstract|abstract[63]	new|new[63]	_	_
10-38	1207-1210	and	abstract[63]	new[63]	_	_
10-39	1211-1224	drug-delivery	abstract|abstract[63]	new|new[63]	_	_
10-40	1225-1232	systems	abstract[63]	new[63]	_	_
10-41	1233-1234	.	_	_	_	_

#Text=However , stability of sustained-release formulations in aqueous solution , long delivery times , and low delivery efficiency are only a small part of the challenges highlighted by researchers .
11-1	1235-1242	However	_	_	_	_
11-2	1243-1244	,	_	_	_	_
11-3	1245-1254	stability	abstract[64]	new[64]	_	_
11-4	1255-1257	of	abstract[64]	new[64]	_	_
11-5	1258-1275	sustained-release	abstract[64]|substance[65]	new[64]|new[65]	_	_
11-6	1276-1288	formulations	abstract[64]|substance[65]	new[64]|new[65]	_	_
11-7	1289-1291	in	abstract[64]|substance[65]	new[64]|new[65]	_	_
11-8	1292-1299	aqueous	abstract[64]|substance[65]|substance[66]	new[64]|new[65]|new[66]	_	_
11-9	1300-1308	solution	abstract[64]|substance[65]|substance[66]	new[64]|new[65]|new[66]	_	_
11-10	1309-1310	,	abstract[64]|substance[65]	new[64]|new[65]	_	_
11-11	1311-1315	long	abstract[64]|substance[65]|time[68]	new[64]|new[65]|new[68]	_	_
11-12	1316-1324	delivery	abstract[64]|substance[65]|abstract|time[68]	new[64]|new[65]|giv|new[68]	coref	11-17
11-13	1325-1330	times	abstract[64]|substance[65]|time[68]	new[64]|new[65]|new[68]	_	_
11-14	1331-1332	,	abstract[64]|substance[65]	new[64]|new[65]	_	_
11-15	1333-1336	and	abstract[64]|substance[65]	new[64]|new[65]	_	_
11-16	1337-1340	low	abstract[64]|substance[65]|abstract[70]	new[64]|new[65]|new[70]	_	_
11-17	1341-1349	delivery	abstract[64]|substance[65]|abstract|abstract[70]	new[64]|new[65]|giv|new[70]	coref	15-12[103_0]
11-18	1350-1360	efficiency	abstract[64]|substance[65]|abstract[70]	new[64]|new[65]|new[70]	_	_
11-19	1361-1364	are	_	_	_	_
11-20	1365-1369	only	_	_	_	_
11-21	1370-1371	a	_	_	_	_
11-22	1372-1377	small	_	_	_	_
11-23	1378-1382	part	_	_	_	_
11-24	1383-1385	of	_	_	_	_
11-25	1386-1389	the	abstract[71]	new[71]	_	_
11-26	1390-1400	challenges	abstract[71]	new[71]	_	_
11-27	1401-1412	highlighted	abstract[71]	new[71]	_	_
11-28	1413-1415	by	abstract[71]	new[71]	_	_
11-29	1416-1427	researchers	abstract[71]|person	new[71]|new	_	_
11-30	1428-1429	.	_	_	_	_

#Text=Dendrigraft
12-1	1430-1441	Dendrigraft	object	new	_	_

#Text=poly-l-lysines ( DGL ) have emerged as a new kind of synthetic polymer consisting of lysine and have been employed as drug- or gene-delivery carriers , due to their biodegradability and rich external amino groups that can encapsulate drugs by the emulsion crosslinking method or plasmid DNA through electric interactions .
13-1	1442-1456	poly-l-lysines	substance	new	_	_
13-2	1457-1458	(	_	_	_	_
13-3	1459-1462	DGL	abstract	new	coref	21-10[151_0]
13-4	1463-1464	)	_	_	_	_
13-5	1465-1469	have	_	_	_	_
13-6	1470-1477	emerged	_	_	_	_
13-7	1478-1480	as	_	_	_	_
13-8	1481-1482	a	_	_	_	_
13-9	1483-1486	new	_	_	_	_
13-10	1487-1491	kind	substance[76]	new[76]	_	_
13-11	1492-1494	of	substance[76]	new[76]	_	_
13-12	1495-1504	synthetic	substance[76]	new[76]	_	_
13-13	1505-1512	polymer	substance[76]	new[76]	_	_
13-14	1513-1523	consisting	substance[76]	new[76]	_	_
13-15	1524-1526	of	substance[76]	new[76]	_	_
13-16	1527-1533	lysine	substance[76]|substance	new[76]|new	_	_
13-17	1534-1537	and	_	_	_	_
13-18	1538-1542	have	_	_	_	_
13-19	1543-1547	been	_	_	_	_
13-20	1548-1556	employed	_	_	_	_
13-21	1557-1559	as	_	_	_	_
13-22	1560-1565	drug-	substance|abstract[80]	new|new[80]	ana	13-29[0_80]
13-23	1566-1568	or	abstract[80]	new[80]	_	_
13-24	1569-1582	gene-delivery	abstract|abstract[80]	new|new[80]	_	_
13-25	1583-1591	carriers	abstract[80]	new[80]	_	_
13-26	1592-1593	,	_	_	_	_
13-27	1594-1597	due	_	_	_	_
13-28	1598-1600	to	_	_	_	_
13-29	1601-1606	their	abstract|abstract[82]	giv|new[82]	coref	14-2[93_82]
13-30	1607-1623	biodegradability	abstract[82]	new[82]	_	_
13-31	1624-1627	and	_	_	_	_
13-32	1628-1632	rich	person[84]	new[84]	ana	14-2[0_84]
13-33	1633-1641	external	person[84]	new[84]	_	_
13-34	1642-1647	amino	object|person[84]	new|new[84]	_	_
13-35	1648-1654	groups	person[84]	new[84]	_	_
13-36	1655-1659	that	person[84]	new[84]	_	_
13-37	1660-1663	can	person[84]	new[84]	_	_
13-38	1664-1675	encapsulate	person[84]	new[84]	_	_
13-39	1676-1681	drugs	person[84]|substance	new[84]|giv	coref	15-15[105_0]
13-40	1682-1684	by	person[84]	new[84]	_	_
13-41	1685-1688	the	person[84]|abstract[88]	new[84]|new[88]	_	_
13-42	1689-1697	emulsion	person[84]|event|abstract[88]	new[84]|new|new[88]	_	_
13-43	1698-1710	crosslinking	person[84]|event|abstract[88]	new[84]|new|new[88]	_	_
13-44	1711-1717	method	person[84]|abstract[88]	new[84]|new[88]	_	_
13-45	1718-1720	or	person[84]	new[84]	_	_
13-46	1721-1728	plasmid	person[84]|object|abstract[90]	new[84]|new|new[90]	_	_
13-47	1729-1732	DNA	person[84]|abstract[90]	new[84]|new[90]	_	_
13-48	1733-1740	through	person[84]	new[84]	_	_
13-49	1741-1749	electric	person[84]|event[91]	new[84]|new[91]	_	_
13-50	1750-1762	interactions	person[84]|event[91]	new[84]|new[91]	_	_
13-51	1763-1764	.	_	_	_	_

#Text=Besides their biodegradability , they can also be modified with targeting ligands and polyethylene glycol ( PEG ) , thereby rendering vectors with targeting properties and long circulation .
14-1	1765-1772	Besides	_	_	_	_
14-2	1773-1778	their	person|abstract[93]	giv|giv[93]	ana	14-5
14-3	1779-1795	biodegradability	abstract[93]	giv[93]	_	_
14-4	1796-1797	,	_	_	_	_
14-5	1798-1802	they	person	giv	_	_
14-6	1803-1806	can	_	_	_	_
14-7	1807-1811	also	_	_	_	_
14-8	1812-1814	be	_	_	_	_
14-9	1815-1823	modified	_	_	_	_
14-10	1824-1828	with	_	_	_	_
14-11	1829-1838	targeting	substance[95]	new[95]	_	_
14-12	1839-1846	ligands	substance[95]	new[95]	_	_
14-13	1847-1850	and	_	_	_	_
14-14	1851-1863	polyethylene	substance|substance[97]	new|new[97]	_	_
14-15	1864-1870	glycol	substance[97]	new[97]	_	_
14-16	1871-1872	(	_	_	_	_
14-17	1873-1876	PEG	object	new	_	_
14-18	1877-1878	)	_	_	_	_
14-19	1879-1880	,	_	_	_	_
14-20	1881-1888	thereby	_	_	_	_
14-21	1889-1898	rendering	_	_	_	_
14-22	1899-1906	vectors	object	new	_	_
14-23	1907-1911	with	_	_	_	_
14-24	1912-1921	targeting	abstract[100]	new[100]	_	_
14-25	1922-1932	properties	abstract[100]	new[100]	_	_
14-26	1933-1936	and	_	_	_	_
14-27	1937-1941	long	abstract[101]	new[101]	_	_
14-28	1942-1953	circulation	abstract[101]	new[101]	_	_
14-29	1954-1955	.	_	_	_	_

#Text=As yet , there are only a few ways available for targeted delivery of anticancer drugs .
15-1	1956-1958	As	_	_	_	_
15-2	1959-1962	yet	_	_	_	_
15-3	1963-1964	,	_	_	_	_
15-4	1965-1970	there	_	_	_	_
15-5	1971-1974	are	_	_	_	_
15-6	1975-1979	only	abstract[102]	new[102]	_	_
15-7	1980-1981	a	abstract[102]	new[102]	_	_
15-8	1982-1985	few	abstract[102]	new[102]	_	_
15-9	1986-1990	ways	abstract[102]	new[102]	_	_
15-10	1991-2000	available	abstract[102]	new[102]	_	_
15-11	2001-2004	for	_	_	_	_
15-12	2005-2013	targeted	abstract[103]	giv[103]	_	_
15-13	2014-2022	delivery	abstract[103]	giv[103]	_	_
15-14	2023-2025	of	abstract[103]	giv[103]	_	_
15-15	2026-2036	anticancer	abstract[103]|abstract|substance[105]	giv[103]|giv|giv[105]	coref|coref	17-10|17-10[120_105]
15-16	2037-2042	drugs	abstract[103]|substance[105]	giv[103]|giv[105]	_	_
15-17	2043-2044	.	_	_	_	_

#Text=Recently , a report showed that VAR2CSA , which is exposed on the membrane of Plasmodium falciparum infected red blood cells ( iRBC ) , could bind to 90 % of tumors , which was verified by running immunohistochemistry on a tumor-tissue array .
16-1	2045-2053	Recently	_	_	_	_
16-2	2054-2055	,	_	_	_	_
16-3	2056-2057	a	abstract[106]	new[106]	_	_
16-4	2058-2064	report	abstract[106]	new[106]	_	_
16-5	2065-2071	showed	_	_	_	_
16-6	2072-2076	that	_	_	_	_
16-7	2077-2084	VAR2CSA	abstract[107]	new[107]	coref	17-3[0_107]
16-8	2085-2086	,	abstract[107]	new[107]	_	_
16-9	2087-2092	which	abstract[107]	new[107]	_	_
16-10	2093-2095	is	abstract[107]	new[107]	_	_
16-11	2096-2103	exposed	abstract[107]	new[107]	_	_
16-12	2104-2106	on	abstract[107]	new[107]	_	_
16-13	2107-2110	the	abstract[107]|place[108]	new[107]|new[108]	_	_
16-14	2111-2119	membrane	abstract[107]|place[108]	new[107]|new[108]	_	_
16-15	2120-2122	of	abstract[107]|place[108]	new[107]|new[108]	_	_
16-16	2123-2133	Plasmodium	abstract[107]|place[108]|substance|plant[112]	new[107]|new[108]|new|new[112]	coref	23-42[173_112]
16-17	2134-2144	falciparum	abstract[107]|place[108]|object|plant[112]	new[107]|new[108]|new|new[112]	_	_
16-18	2145-2153	infected	abstract[107]|place[108]|plant[112]	new[107]|new[108]|new[112]	_	_
16-19	2154-2157	red	abstract[107]|place[108]|substance[111]|plant[112]	new[107]|new[108]|new[111]|new[112]	_	_
16-20	2158-2163	blood	abstract[107]|place[108]|substance[111]|plant[112]	new[107]|new[108]|new[111]|new[112]	_	_
16-21	2164-2169	cells	abstract[107]|place[108]|plant[112]	new[107]|new[108]|new[112]	_	_
16-22	2170-2171	(	_	_	_	_
16-23	2172-2176	iRBC	abstract	new	coref	18-11[126_0]
16-24	2177-2178	)	_	_	_	_
16-25	2179-2180	,	_	_	_	_
16-26	2181-2186	could	_	_	_	_
16-27	2187-2191	bind	_	_	_	_
16-28	2192-2194	to	_	_	_	_
16-29	2195-2197	90	abstract[114]	new[114]	_	_
16-30	2198-2199	%	abstract[114]	new[114]	_	_
16-31	2200-2202	of	abstract[114]	new[114]	_	_
16-32	2203-2209	tumors	abstract[114]|object	new[114]|new	_	_
16-33	2210-2211	,	_	_	_	_
16-34	2212-2217	which	_	_	_	_
16-35	2218-2221	was	_	_	_	_
16-36	2222-2230	verified	_	_	_	_
16-37	2231-2233	by	_	_	_	_
16-38	2234-2241	running	_	_	_	_
16-39	2242-2262	immunohistochemistry	abstract	new	_	_
16-40	2263-2265	on	_	_	_	_
16-41	2266-2267	a	object[117]	new[117]	_	_
16-42	2268-2280	tumor-tissue	object[117]	new[117]	_	_
16-43	2281-2286	array	object[117]	new[117]	_	_
16-44	2287-2288	.	_	_	_	_

#Text=Therefore , VAR2CSA is becoming an attractive target for anticancer drugs ’ development .
17-1	2289-2298	Therefore	_	_	_	_
17-2	2299-2300	,	_	_	_	_
17-3	2301-2308	VAR2CSA	abstract	giv	coref	18-33
17-4	2309-2311	is	_	_	_	_
17-5	2312-2320	becoming	_	_	_	_
17-6	2321-2323	an	_	_	_	_
17-7	2324-2334	attractive	_	_	_	_
17-8	2335-2341	target	_	_	_	_
17-9	2342-2345	for	_	_	_	_
17-10	2346-2356	anticancer	abstract|substance[120]|event[121]	giv|giv[120]|new[121]	coref|coref	28-9[205_121]|31-9
17-11	2357-2362	drugs	substance[120]|event[121]	giv[120]|new[121]	_	_
17-12	2363-2364	’	substance[120]|event[121]	giv[120]|new[121]	_	_
17-13	2365-2376	development	event[121]	new[121]	_	_
17-14	2377-2378	.	_	_	_	_

#Text=P. falciparum infection during pregnancy results in the sequestration of iRBC in the placenta by adhering to a distinct type of chondroitin sulfate A ( CSA ) exclusively expressed on trophoblast via VAR2CSA .
18-1	2379-2381	P.	place[122]|event[123]	new[122]|new[123]	_	_
18-2	2382-2392	falciparum	place[122]|event[123]	new[122]|new[123]	_	_
18-3	2393-2402	infection	event[123]	new[123]	_	_
18-4	2403-2409	during	event[123]	new[123]	_	_
18-5	2410-2419	pregnancy	event[123]|event	new[123]|new	_	_
18-6	2420-2427	results	_	_	_	_
18-7	2428-2430	in	_	_	_	_
18-8	2431-2434	the	event[125]	new[125]	_	_
18-9	2435-2448	sequestration	event[125]	new[125]	_	_
18-10	2449-2451	of	event[125]	new[125]	_	_
18-11	2452-2456	iRBC	event[125]|abstract[126]	new[125]|giv[126]	_	_
18-12	2457-2459	in	event[125]|abstract[126]	new[125]|giv[126]	_	_
18-13	2460-2463	the	event[125]|abstract[126]|place[127]	new[125]|giv[126]|new[127]	coref	20-5[0_127]
18-14	2464-2472	placenta	event[125]|abstract[126]|place[127]	new[125]|giv[126]|new[127]	_	_
18-15	2473-2475	by	_	_	_	_
18-16	2476-2484	adhering	_	_	_	_
18-17	2485-2487	to	_	_	_	_
18-18	2488-2489	a	abstract[128]	new[128]	_	_
18-19	2490-2498	distinct	abstract[128]	new[128]	_	_
18-20	2499-2503	type	abstract[128]	new[128]	_	_
18-21	2504-2506	of	abstract[128]	new[128]	_	_
18-22	2507-2518	chondroitin	abstract[128]|substance[129]	new[128]|new[129]	_	_
18-23	2519-2526	sulfate	abstract[128]|substance[129]	new[128]|new[129]	_	_
18-24	2527-2528	A	abstract[128]|substance[129]	new[128]|new[129]	_	_
18-25	2529-2530	(	_	_	_	_
18-26	2531-2534	CSA	abstract	new	coref	19-12
18-27	2535-2536	)	_	_	_	_
18-28	2537-2548	exclusively	_	_	_	_
18-29	2549-2558	expressed	_	_	_	_
18-30	2559-2561	on	_	_	_	_
18-31	2562-2573	trophoblast	animal	new	_	_
18-32	2574-2577	via	_	_	_	_
18-33	2578-2585	VAR2CSA	abstract	giv	coref	19-5
18-34	2586-2587	.	_	_	_	_

#Text=Short continuous regions of VAR2CSA with affinity for multiple types of CSA were defined .
19-1	2588-2593	Short	place[133]	new[133]	_	_
19-2	2594-2604	continuous	place[133]	new[133]	_	_
19-3	2605-2612	regions	place[133]	new[133]	_	_
19-4	2613-2615	of	place[133]	new[133]	_	_
19-5	2616-2623	VAR2CSA	place[133]|abstract	new[133]|giv	coref	20-13
19-6	2624-2628	with	place[133]	new[133]	_	_
19-7	2629-2637	affinity	place[133]|abstract[135]	new[133]|new[135]	_	_
19-8	2638-2641	for	place[133]|abstract[135]	new[133]|new[135]	_	_
19-9	2642-2650	multiple	place[133]|abstract[135]|abstract[136]	new[133]|new[135]|new[136]	_	_
19-10	2651-2656	types	place[133]|abstract[135]|abstract[136]	new[133]|new[135]|new[136]	_	_
19-11	2657-2659	of	place[133]|abstract[135]|abstract[136]	new[133]|new[135]|new[136]	_	_
19-12	2660-2663	CSA	place[133]|abstract[135]|abstract[136]|abstract	new[133]|new[135]|new[136]|giv	_	_
19-13	2664-2668	were	_	_	_	_
19-14	2669-2676	defined	_	_	_	_
19-15	2677-2678	.	_	_	_	_

#Text=A 28 amino acids placenta CSA-binding peptide ( plCSA-BP ) from the VAR2CSA region was recently tested as a guide peptide for targeted delivery of doxorubicin to choriocarcinoma .
20-1	2679-2680	A	abstract[141]	new[141]	appos	20-9[0_141]
20-2	2681-2683	28	person[138]|abstract[141]	new[138]|new[141]	_	_
20-3	2684-2689	amino	person[138]|abstract[141]	new[138]|new[141]	_	_
20-4	2690-2695	acids	person[138]|abstract[141]	new[138]|new[141]	_	_
20-5	2696-2704	placenta	place|abstract[140]|abstract[141]	giv|new[140]|new[141]	_	_
20-6	2705-2716	CSA-binding	abstract[140]|abstract[141]	new[140]|new[141]	_	_
20-7	2717-2724	peptide	abstract[141]	new[141]	_	_
20-8	2725-2726	(	_	_	_	_
20-9	2727-2735	plCSA-BP	abstract	giv	coref	29-27
20-10	2736-2737	)	_	_	_	_
20-11	2738-2742	from	_	_	_	_
20-12	2743-2746	the	place[144]	giv[144]	_	_
20-13	2747-2754	VAR2CSA	abstract|place[144]	giv|giv[144]	_	_
20-14	2755-2761	region	place[144]	giv[144]	_	_
20-15	2762-2765	was	_	_	_	_
20-16	2766-2774	recently	_	_	_	_
20-17	2775-2781	tested	_	_	_	_
20-18	2782-2784	as	_	_	_	_
20-19	2785-2786	a	abstract[146]	new[146]	coref	29-29[217_146]
20-20	2787-2792	guide	object|abstract[146]	new|new[146]	coref	29-30
20-21	2793-2800	peptide	abstract[146]	new[146]	_	_
20-22	2801-2804	for	abstract[146]	new[146]	_	_
20-23	2805-2813	targeted	abstract[146]|event[147]	new[146]|new[147]	ana	21-4[0_147]
20-24	2814-2822	delivery	abstract[146]|event[147]	new[146]|new[147]	_	_
20-25	2823-2825	of	abstract[146]|event[147]	new[146]|new[147]	_	_
20-26	2826-2837	doxorubicin	abstract[146]|event[147]|substance	new[146]|new[147]|new	_	_
20-27	2838-2840	to	abstract[146]|event[147]	new[146]|new[147]	_	_
20-28	2841-2856	choriocarcinoma	abstract[146]|event[147]|abstract	new[146]|new[147]|new	coref	24-12
20-29	2857-2858	.	_	_	_	_

#Text=However , whether it could be used to modify the DGL and its bioactivity after the modification was not evaluated .
21-1	2859-2866	However	_	_	_	_
21-2	2867-2868	,	_	_	_	_
21-3	2869-2876	whether	_	_	_	_
21-4	2877-2879	it	event	giv	ana	21-13
21-5	2880-2885	could	_	_	_	_
21-6	2886-2888	be	_	_	_	_
21-7	2889-2893	used	_	_	_	_
21-8	2894-2896	to	_	_	_	_
21-9	2897-2903	modify	_	_	_	_
21-10	2904-2907	the	abstract[151]	giv[151]	coref	29-36[0_151]
21-11	2908-2911	DGL	abstract[151]	giv[151]	_	_
21-12	2912-2915	and	_	_	_	_
21-13	2916-2919	its	event|substance[153]	giv|new[153]	coref	29-12[209_0]
21-14	2920-2931	bioactivity	substance[153]	new[153]	_	_
21-15	2932-2937	after	substance[153]	new[153]	_	_
21-16	2938-2941	the	substance[153]|event[154]	new[153]|new[154]	_	_
21-17	2942-2954	modification	substance[153]|event[154]	new[153]|new[154]	_	_
21-18	2955-2958	was	_	_	_	_
21-19	2959-2962	not	_	_	_	_
21-20	2963-2972	evaluated	_	_	_	_
21-21	2973-2974	.	_	_	_	_

#Text=The immunosuppressive , antimalarial , and pro-cytotoxic bacterial prodigiosin was recently described as a potent antimetastatic and anticancer agent .
22-1	2975-2978	The	animal[155]	new[155]	coref	24-3[0_155]
22-2	2979-2996	immunosuppressive	animal[155]	new[155]	_	_
22-3	2997-2998	,	animal[155]	new[155]	_	_
22-4	2999-3011	antimalarial	animal[155]	new[155]	_	_
22-5	3012-3013	,	animal[155]	new[155]	_	_
22-6	3014-3017	and	animal[155]	new[155]	_	_
22-7	3018-3031	pro-cytotoxic	animal[155]	new[155]	_	_
22-8	3032-3041	bacterial	animal[155]	new[155]	_	_
22-9	3042-3053	prodigiosin	animal[155]	new[155]	_	_
22-10	3054-3057	was	_	_	_	_
22-11	3058-3066	recently	_	_	_	_
22-12	3067-3076	described	_	_	_	_
22-13	3077-3079	as	_	_	_	_
22-14	3080-3081	a	substance[156]	new[156]	ana	23-1[0_156]
22-15	3082-3088	potent	substance[156]	new[156]	_	_
22-16	3089-3103	antimetastatic	substance[156]	new[156]	_	_
22-17	3104-3107	and	substance[156]	new[156]	_	_
22-18	3108-3118	anticancer	substance[156]	new[156]	_	_
22-19	3119-3124	agent	substance[156]	new[156]	_	_
22-20	3125-3126	.	_	_	_	_

#Text=It can induce apoptosis in a wide range of cancer cell lines , including hematopoietic cancer , breast cancer , gastric cancer , colon cancer , lung cancer , and rat hepatocellular carcinoma cell lines , with no marked toxicity in nonmalignant cells .
23-1	3127-3129	It	substance	giv	coref	25-14[182_0]
23-2	3130-3133	can	_	_	_	_
23-3	3134-3140	induce	_	_	_	_
23-4	3141-3150	apoptosis	abstract	new	coref	25-6[178_0]
23-5	3151-3153	in	_	_	_	_
23-6	3154-3155	a	abstract[159]	new[159]	_	_
23-7	3156-3160	wide	abstract[159]	new[159]	_	_
23-8	3161-3166	range	abstract[159]	new[159]	_	_
23-9	3167-3169	of	abstract[159]	new[159]	_	_
23-10	3170-3176	cancer	abstract[159]|abstract|object[162]	new[159]|giv|new[162]	coref|coref	23-15[163_0]|23-31[171_162]
23-11	3177-3181	cell	abstract[159]|place|object[162]	new[159]|new|new[162]	coref	23-34
23-12	3182-3187	lines	abstract[159]|object[162]	new[159]|new[162]	_	_
23-13	3188-3189	,	abstract[159]|object[162]	new[159]|new[162]	_	_
23-14	3190-3199	including	abstract[159]|object[162]	new[159]|new[162]	_	_
23-15	3200-3213	hematopoietic	abstract[159]|object[162]|abstract[163]	new[159]|new[162]|giv[163]	coref	23-18[164_163]
23-16	3214-3220	cancer	abstract[159]|object[162]|abstract[163]	new[159]|new[162]|giv[163]	_	_
23-17	3221-3222	,	abstract[159]|object[162]	new[159]|new[162]	_	_
23-18	3223-3229	breast	abstract[159]|object[162]|abstract[164]	new[159]|new[162]|giv[164]	coref	23-21[165_164]
23-19	3230-3236	cancer	abstract[159]|object[162]|abstract[164]	new[159]|new[162]|giv[164]	_	_
23-20	3237-3238	,	abstract[159]|object[162]	new[159]|new[162]	_	_
23-21	3239-3246	gastric	abstract[159]|object[162]|abstract[165]	new[159]|new[162]|giv[165]	coref	23-24[166_165]
23-22	3247-3253	cancer	abstract[159]|object[162]|abstract[165]	new[159]|new[162]|giv[165]	_	_
23-23	3254-3255	,	abstract[159]|object[162]	new[159]|new[162]	_	_
23-24	3256-3261	colon	abstract[159]|object[162]|abstract[166]	new[159]|new[162]|giv[166]	coref	23-27[167_166]
23-25	3262-3268	cancer	abstract[159]|object[162]|abstract[166]	new[159]|new[162]|giv[166]	_	_
23-26	3269-3270	,	abstract[159]|object[162]	new[159]|new[162]	_	_
23-27	3271-3275	lung	abstract[159]|object[162]|abstract[167]	new[159]|new[162]|giv[167]	coref	32-30[0_167]
23-28	3276-3282	cancer	abstract[159]|object[162]|abstract[167]	new[159]|new[162]|giv[167]	_	_
23-29	3283-3284	,	abstract[159]|object[162]	new[159]|new[162]	_	_
23-30	3285-3288	and	abstract[159]|object[162]	new[159]|new[162]	_	_
23-31	3289-3292	rat	abstract[159]|object[162]|animal|object[171]	new[159]|new[162]|new|giv[171]	_	_
23-32	3293-3307	hepatocellular	abstract[159]|object[162]|substance[169]|object[171]	new[159]|new[162]|new[169]|giv[171]	_	_
23-33	3308-3317	carcinoma	abstract[159]|object[162]|substance[169]|object[171]	new[159]|new[162]|new[169]|giv[171]	_	_
23-34	3318-3322	cell	abstract[159]|object[162]|place|object[171]	new[159]|new[162]|giv|giv[171]	coref	30-23
23-35	3323-3328	lines	abstract[159]|object[162]|object[171]	new[159]|new[162]|giv[171]	_	_
23-36	3329-3330	,	_	_	_	_
23-37	3331-3335	with	_	_	_	_
23-38	3336-3338	no	abstract[172]	giv[172]	_	_
23-39	3339-3345	marked	abstract[172]	giv[172]	_	_
23-40	3346-3354	toxicity	abstract[172]	giv[172]	_	_
23-41	3355-3357	in	abstract[172]	giv[172]	_	_
23-42	3358-3370	nonmalignant	abstract[172]|plant[173]	giv[172]|giv[173]	coref	25-8[180_173]
23-43	3371-3376	cells	abstract[172]|plant[173]	giv[172]|giv[173]	_	_
23-44	3377-3378	.	_	_	_	_

#Text=However , prodigiosin has not been reported for the treatment of choriocarcinoma yet .
24-1	3379-3386	However	_	_	_	_
24-2	3387-3388	,	_	_	_	_
24-3	3389-3400	prodigiosin	animal	giv	coref	25-13
24-4	3401-3404	has	_	_	_	_
24-5	3405-3408	not	_	_	_	_
24-6	3409-3413	been	_	_	_	_
24-7	3414-3422	reported	_	_	_	_
24-8	3423-3426	for	_	_	_	_
24-9	3427-3430	the	abstract[175]	new[175]	_	_
24-10	3431-3440	treatment	abstract[175]	new[175]	_	_
24-11	3441-3443	of	abstract[175]	new[175]	_	_
24-12	3444-3459	choriocarcinoma	abstract[175]|abstract	new[175]|giv	ana	25-1
24-13	3460-3463	yet	_	_	_	_
24-14	3464-3465	.	_	_	_	_

#Text=It is selective in promoting apoptosis of malignant tumor cells , rendering prodigiosin a promising anticancer agent .
25-1	3466-3468	It	abstract	giv	coref	30-22
25-2	3469-3471	is	_	_	_	_
25-3	3472-3481	selective	_	_	_	_
25-4	3482-3484	in	_	_	_	_
25-5	3485-3494	promoting	_	_	_	_
25-6	3495-3504	apoptosis	abstract[178]	giv[178]	_	_
25-7	3505-3507	of	abstract[178]	giv[178]	_	_
25-8	3508-3517	malignant	abstract[178]|plant[180]	giv[178]|giv[180]	_	_
25-9	3518-3523	tumor	abstract[178]|object|plant[180]	giv[178]|new|giv[180]	coref	30-30
25-10	3524-3529	cells	abstract[178]|plant[180]	giv[178]|giv[180]	_	_
25-11	3530-3531	,	_	_	_	_
25-12	3532-3541	rendering	_	_	_	_
25-13	3542-3553	prodigiosin	animal	giv	coref	26-5
25-14	3554-3555	a	substance[182]	giv[182]	_	_
25-15	3556-3565	promising	substance[182]	giv[182]	_	_
25-16	3566-3576	anticancer	substance[182]	giv[182]	_	_
25-17	3577-3582	agent	substance[182]	giv[182]	_	_
25-18	3583-3584	.	_	_	_	_

#Text=The antitumor mechanism of prodigiosin is still unclear , especially in regard to newly acquired prodigiosin produced by a small number of microorganisms , including Serratia marcescens and other bacteria , such as Streptomyces griseoviridis , Serratia spp. , Zooshikellarubidus , Vibrio sp. , Actinomycetes , and Hahella chejuensis .
26-1	3585-3588	The	abstract[184]	new[184]	_	_
26-2	3589-3598	antitumor	abstract|abstract[184]	new|new[184]	_	_
26-3	3599-3608	mechanism	abstract[184]	new[184]	_	_
26-4	3609-3611	of	abstract[184]	new[184]	_	_
26-5	3612-3623	prodigiosin	abstract[184]|animal	new[184]|giv	coref	26-14[186_0]
26-6	3624-3626	is	_	_	_	_
26-7	3627-3632	still	_	_	_	_
26-8	3633-3640	unclear	_	_	_	_
26-9	3641-3642	,	_	_	_	_
26-10	3643-3653	especially	_	_	_	_
26-11	3654-3656	in	_	_	_	_
26-12	3657-3663	regard	_	_	_	_
26-13	3664-3666	to	_	_	_	_
26-14	3667-3672	newly	animal[186]	giv[186]	coref	28-1[0_186]
26-15	3673-3681	acquired	animal[186]	giv[186]	_	_
26-16	3682-3693	prodigiosin	animal[186]	giv[186]	_	_
26-17	3694-3702	produced	animal[186]	giv[186]	_	_
26-18	3703-3705	by	animal[186]	giv[186]	_	_
26-19	3706-3707	a	animal[186]|abstract[187]	giv[186]|new[187]	_	_
26-20	3708-3713	small	animal[186]|abstract[187]	giv[186]|new[187]	_	_
26-21	3714-3720	number	animal[186]|abstract[187]	giv[186]|new[187]	_	_
26-22	3721-3723	of	animal[186]|abstract[187]	giv[186]|new[187]	_	_
26-23	3724-3738	microorganisms	animal[186]|abstract[187]|abstract[188]	giv[186]|new[187]|new[188]	_	_
26-24	3739-3740	,	animal[186]|abstract[187]|abstract[188]	giv[186]|new[187]|new[188]	_	_
26-25	3741-3750	including	animal[186]|abstract[187]|abstract[188]	giv[186]|new[187]|new[188]	_	_
26-26	3751-3759	Serratia	animal[186]|abstract[187]|abstract[188]|abstract[189]	giv[186]|new[187]|new[188]|new[189]	coref	26-37[0_189]
26-27	3760-3770	marcescens	animal[186]|abstract[187]|abstract[188]|abstract[189]	giv[186]|new[187]|new[188]|new[189]	_	_
26-28	3771-3774	and	animal[186]|abstract[187]|abstract[188]|abstract[189]	giv[186]|new[187]|new[188]|new[189]	_	_
26-29	3775-3780	other	animal[186]|abstract[187]|abstract[188]|abstract[189]|animal[190]	giv[186]|new[187]|new[188]|new[189]|new[190]	_	_
26-30	3781-3789	bacteria	animal[186]|abstract[187]|abstract[188]|abstract[189]|animal[190]	giv[186]|new[187]|new[188]|new[189]|new[190]	_	_
26-31	3790-3791	,	animal[186]|abstract[187]|abstract[188]|abstract[189]	giv[186]|new[187]|new[188]|new[189]	_	_
26-32	3792-3796	such	animal[186]|abstract[187]|abstract[188]|abstract[189]	giv[186]|new[187]|new[188]|new[189]	_	_
26-33	3797-3799	as	animal[186]|abstract[187]|abstract[188]|abstract[189]	giv[186]|new[187]|new[188]|new[189]	_	_
26-34	3800-3812	Streptomyces	animal[186]|abstract[187]|abstract[188]|abstract[189]|animal	giv[186]|new[187]|new[188]|new[189]|new	_	_
26-35	3813-3826	griseoviridis	animal[186]|abstract[187]|abstract[188]|abstract[189]	giv[186]|new[187]|new[188]|new[189]	_	_
26-36	3827-3828	,	animal[186]|abstract[187]|abstract[188]|abstract[189]	giv[186]|new[187]|new[188]|new[189]	_	_
26-37	3829-3837	Serratia	animal[186]|abstract[187]|abstract[188]|abstract[189]|abstract	giv[186]|new[187]|new[188]|new[189]|giv	coref	29-45
26-38	3838-3842	spp.	animal[186]|abstract[187]|abstract[188]|abstract[189]	giv[186]|new[187]|new[188]|new[189]	_	_
26-39	3843-3844	,	animal[186]|abstract[187]|abstract[188]|abstract[189]	giv[186]|new[187]|new[188]|new[189]	_	_
26-40	3845-3863	Zooshikellarubidus	animal[186]|abstract[187]|abstract[188]|abstract[189]|abstract	giv[186]|new[187]|new[188]|new[189]|new	_	_
26-41	3864-3865	,	animal[186]|abstract[187]|abstract[188]|abstract[189]	giv[186]|new[187]|new[188]|new[189]	_	_
26-42	3866-3872	Vibrio	animal[186]|abstract[187]|abstract[188]|abstract[189]|substance|plant[195]	giv[186]|new[187]|new[188]|new[189]|new|new[195]	_	_
26-43	3873-3876	sp.	animal[186]|abstract[187]|abstract[188]|abstract[189]|plant[195]	giv[186]|new[187]|new[188]|new[189]|new[195]	_	_
26-44	3877-3878	,	animal[186]|abstract[187]|abstract[188]|abstract[189]	giv[186]|new[187]|new[188]|new[189]	_	_
26-45	3879-3892	Actinomycetes	animal[186]|abstract[187]|abstract[188]|abstract[189]|substance	giv[186]|new[187]|new[188]|new[189]|new	_	_
26-46	3893-3894	,	animal[186]|abstract[187]|abstract[188]|abstract[189]	giv[186]|new[187]|new[188]|new[189]	_	_
26-47	3895-3898	and	animal[186]|abstract[187]|abstract[188]|abstract[189]	giv[186]|new[187]|new[188]|new[189]	_	_
26-48	3899-3906	Hahella	animal[186]|abstract[187]|abstract[188]|abstract[189]|person|abstract[198]	giv[186]|new[187]|new[188]|new[189]|new|new[198]	_	_
26-49	3907-3917	chejuensis	animal[186]|abstract[187]|abstract[188]|abstract[189]|abstract[198]	giv[186]|new[187]|new[188]|new[189]|new[198]	_	_
26-50	3918-3919	.	_	_	_	_

#Text=Research on the mechanism of bacterial origin
27-1	3920-3928	Research	abstract[199]	new[199]	_	_
27-2	3929-3931	on	abstract[199]	new[199]	_	_
27-3	3932-3935	the	abstract[199]|abstract[200]	new[199]|new[200]	_	_
27-4	3936-3945	mechanism	abstract[199]|abstract[200]	new[199]|new[200]	_	_
27-5	3946-3948	of	abstract[199]|abstract[200]	new[199]|new[200]	_	_
27-6	3949-3958	bacterial	abstract[199]|abstract[200]|abstract[201]	new[199]|new[200]|new[201]	_	_
27-7	3959-3965	origin	abstract[199]|abstract[200]|abstract[201]	new[199]|new[200]|new[201]	_	_

#Text=prodigiosin is very important for clinical application and drug development .
28-1	3966-3977	prodigiosin	animal	giv	coref	29-22
28-2	3978-3980	is	_	_	_	_
28-3	3981-3985	very	_	_	_	_
28-4	3986-3995	important	_	_	_	_
28-5	3996-3999	for	_	_	_	_
28-6	4000-4008	clinical	abstract[203]	new[203]	_	_
28-7	4009-4020	application	abstract[203]	new[203]	_	_
28-8	4021-4024	and	_	_	_	_
28-9	4025-4029	drug	substance|event[205]	new|giv[205]	coref	29-12
28-10	4030-4041	development	event[205]	giv[205]	_	_
28-11	4042-4043	.	_	_	_	_

#Text=In this study , to develop a new type of targeted drug delivery carrier material and investigate the anticancer mechanism of prodigiosin , we first used plCSA-BP as a guide peptide to coat on the DGL vector for cancer-cell-targeted delivery of prodigiosin produced from Serratia marcescens subsp . lawsoniana HDZK-BYSB107 .
29-1	4044-4046	In	_	_	_	_
29-2	4047-4051	this	abstract[206]	new[206]	_	_
29-3	4052-4057	study	abstract[206]	new[206]	_	_
29-4	4058-4059	,	_	_	_	_
29-5	4060-4062	to	_	_	_	_
29-6	4063-4070	develop	_	_	_	_
29-7	4071-4072	a	abstract[207]	new[207]	ana	30-14[0_207]
29-8	4073-4076	new	abstract[207]	new[207]	_	_
29-9	4077-4081	type	abstract[207]	new[207]	_	_
29-10	4082-4084	of	abstract[207]	new[207]	_	_
29-11	4085-4093	targeted	abstract[207]|abstract[211]	new[207]|new[211]	_	_
29-12	4094-4098	drug	abstract[207]|substance|event[209]|abstract[211]	new[207]|giv|giv[209]|new[211]	_	_
29-13	4099-4107	delivery	abstract[207]|event[209]|abstract[211]	new[207]|giv[209]|new[211]	_	_
29-14	4108-4115	carrier	abstract[207]|organization|abstract[211]	new[207]|new|new[211]	_	_
29-15	4116-4124	material	abstract[207]|abstract[211]	new[207]|new[211]	_	_
29-16	4125-4128	and	_	_	_	_
29-17	4129-4140	investigate	_	_	_	_
29-18	4141-4144	the	abstract[212]	new[212]	coref	31-4[241_212]
29-19	4145-4155	anticancer	abstract[212]	new[212]	_	_
29-20	4156-4165	mechanism	abstract[212]	new[212]	_	_
29-21	4166-4168	of	abstract[212]	new[212]	_	_
29-22	4169-4180	prodigiosin	abstract[212]|animal	new[212]|giv	coref	29-42[221_0]
29-23	4181-4182	,	_	_	_	_
29-24	4183-4185	we	person	acc	ana	30-3
29-25	4186-4191	first	_	_	_	_
29-26	4192-4196	used	_	_	_	_
29-27	4197-4205	plCSA-BP	abstract	giv	_	_
29-28	4206-4208	as	_	_	_	_
29-29	4209-4210	a	abstract[217]	giv[217]	_	_
29-30	4211-4216	guide	object|abstract[217]	giv|giv[217]	_	_
29-31	4217-4224	peptide	abstract[217]	giv[217]	_	_
29-32	4225-4227	to	abstract[217]	giv[217]	_	_
29-33	4228-4232	coat	abstract[217]	giv[217]	_	_
29-34	4233-4235	on	abstract[217]	giv[217]	_	_
29-35	4236-4239	the	abstract[217]|abstract[219]	giv[217]|giv[219]	coref	32-7[247_219]
29-36	4240-4243	DGL	abstract[217]|abstract|abstract[219]	giv[217]|giv|giv[219]	_	_
29-37	4244-4250	vector	abstract[217]|abstract[219]	giv[217]|giv[219]	_	_
29-38	4251-4254	for	abstract[217]	giv[217]	_	_
29-39	4255-4275	cancer-cell-targeted	abstract[217]|abstract[220]	giv[217]|new[220]	coref	32-13[248_220]
29-40	4276-4284	delivery	abstract[217]|abstract[220]	giv[217]|new[220]	_	_
29-41	4285-4287	of	abstract[217]|abstract[220]	giv[217]|new[220]	_	_
29-42	4288-4299	prodigiosin	abstract[217]|abstract[220]|animal[221]	giv[217]|new[220]|giv[221]	_	_
29-43	4300-4308	produced	abstract[217]|abstract[220]|animal[221]	giv[217]|new[220]|giv[221]	_	_
29-44	4309-4313	from	abstract[217]|abstract[220]|animal[221]	giv[217]|new[220]|giv[221]	_	_
29-45	4314-4322	Serratia	abstract[217]|abstract[220]|animal[221]|abstract|abstract[223]	giv[217]|new[220]|giv[221]|giv|new[223]	appos	29-47[225_223]
29-46	4323-4333	marcescens	abstract[217]|abstract[220]|animal[221]|abstract[223]	giv[217]|new[220]|giv[221]|new[223]	_	_
29-47	4334-4339	subsp	plant|abstract[225]	new|giv[225]	_	_
29-48	4340-4341	.	abstract[225]	giv[225]	_	_
29-49	4342-4352	lawsoniana	abstract[225]	giv[225]	_	_
29-50	4353-4365	HDZK-BYSB107	abstract	new	_	_
29-51	4366-4367	.	_	_	_	_

#Text=Then , we tested the binding ability of the newly developed DGL/CSA-PNPs and its anticancer effect in vitro on a JEG3 choriocarcinoma cell line and in vivo on a tumor model , respectively .
30-1	4368-4372	Then	_	_	_	_
30-2	4373-4374	,	_	_	_	_
30-3	4375-4377	we	person	giv	_	_
30-4	4378-4384	tested	_	_	_	_
30-5	4385-4388	the	abstract[229]	new[229]	_	_
30-6	4389-4396	binding	object|abstract[229]	new|new[229]	_	_
30-7	4397-4404	ability	abstract[229]	new[229]	_	_
30-8	4405-4407	of	abstract[229]	new[229]	_	_
30-9	4408-4411	the	abstract[229]|abstract[230]	new[229]|new[230]	_	_
30-10	4412-4417	newly	abstract[229]|abstract[230]	new[229]|new[230]	_	_
30-11	4418-4427	developed	abstract[229]|abstract[230]	new[229]|new[230]	_	_
30-12	4428-4440	DGL/CSA-PNPs	abstract[229]|abstract[230]	new[229]|new[230]	_	_
30-13	4441-4444	and	abstract[229]	new[229]	_	_
30-14	4445-4448	its	abstract[229]|abstract|abstract[232]	new[229]|giv|new[232]	coref	31-8[243_232]
30-15	4449-4459	anticancer	abstract[229]|abstract[232]	new[229]|new[232]	_	_
30-16	4460-4466	effect	abstract[229]|abstract[232]	new[229]|new[232]	_	_
30-17	4467-4469	in	_	_	_	_
30-18	4470-4475	vitro	abstract	new	_	_
30-19	4476-4478	on	_	_	_	_
30-20	4479-4480	a	object[237]	new[237]	_	_
30-21	4481-4485	JEG3	abstract|object[237]	new|new[237]	_	_
30-22	4486-4501	choriocarcinoma	abstract|object[237]	giv|new[237]	_	_
30-23	4502-4506	cell	place|object[237]	giv|new[237]	_	_
30-24	4507-4511	line	object[237]	new[237]	_	_
30-25	4512-4515	and	_	_	_	_
30-26	4516-4518	in	_	_	_	_
30-27	4519-4523	vivo	abstract	new	_	_
30-28	4524-4526	on	_	_	_	_
30-29	4527-4528	a	abstract[240]	new[240]	_	_
30-30	4529-4534	tumor	object|abstract[240]	giv|new[240]	_	_
30-31	4535-4540	model	abstract[240]	new[240]	_	_
30-32	4541-4542	,	_	_	_	_
30-33	4543-4555	respectively	_	_	_	_
30-34	4556-4557	.	_	_	_	_

#Text=In addition , the mechanism responsible for the anticancer effect of targeted nano-prodigiosin was also investigated .
31-1	4558-4560	In	_	_	_	_
31-2	4561-4569	addition	_	_	_	_
31-3	4570-4571	,	_	_	_	_
31-4	4572-4575	the	abstract[241]	giv[241]	_	_
31-5	4576-4585	mechanism	abstract[241]	giv[241]	_	_
31-6	4586-4597	responsible	abstract[241]	giv[241]	_	_
31-7	4598-4601	for	abstract[241]	giv[241]	_	_
31-8	4602-4605	the	abstract[241]|abstract[243]	giv[241]|giv[243]	_	_
31-9	4606-4616	anticancer	abstract[241]|abstract|abstract[243]	giv[241]|giv|giv[243]	_	_
31-10	4617-4623	effect	abstract[241]|abstract[243]	giv[241]|giv[243]	_	_
31-11	4624-4626	of	abstract[241]|abstract[243]	giv[241]|giv[243]	_	_
31-12	4627-4635	targeted	abstract[241]|abstract[243]|object[244]	giv[241]|giv[243]|new[244]	_	_
31-13	4636-4652	nano-prodigiosin	abstract[241]|abstract[243]|object[244]	giv[241]|giv[243]|new[244]	_	_
31-14	4653-4656	was	_	_	_	_
31-15	4657-4661	also	_	_	_	_
31-16	4662-4674	investigated	_	_	_	_
31-17	4675-4676	.	_	_	_	_

#Text=Overall , these findings suggested that the DGL/CSA vector is an excellent cancer-specific-drug delivery carrier , which has great potential as a novel delivery system for the treatment of cancer .
32-1	4677-4684	Overall	_	_	_	_
32-2	4685-4686	,	_	_	_	_
32-3	4687-4692	these	abstract[245]	new[245]	_	_
32-4	4693-4701	findings	abstract[245]	new[245]	_	_
32-5	4702-4711	suggested	_	_	_	_
32-6	4712-4716	that	_	_	_	_
32-7	4717-4720	the	abstract[247]	giv[247]	coref	32-11[249_247]
32-8	4721-4728	DGL/CSA	organization|abstract[247]	new|giv[247]	_	_
32-9	4729-4735	vector	abstract[247]	giv[247]	_	_
32-10	4736-4738	is	_	_	_	_
32-11	4739-4741	an	abstract[249]	giv[249]	_	_
32-12	4742-4751	excellent	abstract[249]	giv[249]	_	_
32-13	4752-4772	cancer-specific-drug	abstract[248]|abstract[249]	giv[248]|giv[249]	coref	32-24[0_248]
32-14	4773-4781	delivery	abstract[248]|abstract[249]	giv[248]|giv[249]	_	_
32-15	4782-4789	carrier	abstract[249]	giv[249]	_	_
32-16	4790-4791	,	abstract[249]	giv[249]	_	_
32-17	4792-4797	which	abstract[249]	giv[249]	_	_
32-18	4798-4801	has	abstract[249]	giv[249]	_	_
32-19	4802-4807	great	abstract[249]|abstract[250]	giv[249]|new[250]	_	_
32-20	4808-4817	potential	abstract[249]|abstract[250]	giv[249]|new[250]	_	_
32-21	4818-4820	as	abstract[249]	giv[249]	_	_
32-22	4821-4822	a	abstract[249]|abstract[252]	giv[249]|new[252]	_	_
32-23	4823-4828	novel	abstract[249]|abstract[252]	giv[249]|new[252]	_	_
32-24	4829-4837	delivery	abstract[249]|abstract|abstract[252]	giv[249]|giv|new[252]	_	_
32-25	4838-4844	system	abstract[249]|abstract[252]	giv[249]|new[252]	_	_
32-26	4845-4848	for	abstract[249]|abstract[252]	giv[249]|new[252]	_	_
32-27	4849-4852	the	abstract[249]|abstract[252]|abstract[253]	giv[249]|new[252]|new[253]	_	_
32-28	4853-4862	treatment	abstract[249]|abstract[252]|abstract[253]	giv[249]|new[252]|new[253]	_	_
32-29	4863-4865	of	abstract[249]|abstract[252]|abstract[253]	giv[249]|new[252]|new[253]	_	_
32-30	4866-4872	cancer	abstract[249]|abstract[252]|abstract[253]|abstract	giv[249]|new[252]|new[253]|giv	_	_
32-31	4873-4874	.	_	_	_	_
